The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel that is activated by cAMP-dependent phosphorylation. CFTR channel activity is also stimulated by cGMP-dependent protein kinase and protein kinase C. Results: Here, we show that CFTR channel activation by cGMP may also occur directly. In oocytes from onethird of Xenopus donors, the activation of CFTR by cGMP averaged 87 % of the level achieved by cAMP. The currents activated by either cyclic nucleotide displayed similar current-voltage relationships, kinetics, pharmacology and halide selectivity. Sequential stimulation by cAMP and cGMP was not additive, suggesting that both cyclic nucleotides activate the same channel; cGMP was one order of magnitude more potent than cAMP, and its action was insensitive to protein kinase inhibitors. Analysis of the amino-acid sequence of CFTR revealed a domain in the amino-terminal portion of the third cytoplasmic loop that resembles a class of cyclicnucleotide-binding domains related to that of the catabolite-gene activator protein, CAP, Two CFTR residues in this domain -Va397 and Lys420 -were identified which, when changed to alanine, altered the response to cGMP independently of the response to cAMP. Conclusions: We conclude that direct cyclic nucleotide binding may play a role in channel gating of CFTR. The cGMP-binding domain may provide a useful target for pharmacologic intervention in cystic fibrosis.
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Background
The cystic fibrosis transmembrane conductance regulator (CFTR) [1] is a chloride channel that is activated by cAMP-dependent protein kinase (PKA) [2, 3] . The action of PKA leads to opening of the channel by the phosphorylation of multiple sites on the regulatory domain of CFTR, located in the distal portion of the third cytoplasmic loop [4] . Residual activation occurs despite the simultaneous removal of ten phosphorylation sites, suggesting that PKA exerts a portion of its effect through unidentified sites on CFTR or other regulatory proteins [5] . A role for incremental CFTR phosphorylation in the gating of its channel by nucleotides has been suggested recently [6, 7] . Protein kinase C (PKC) phosphorylates CFTR and potentiates channel activation by PKA [5, [8] [9] [10] , but the mechanism of this potentiation has not yet been determined.
Cyclic GMP (cGMP) has long been known to stimulate chloride secretion. In T84 colon carcinoma cells, this may occur by cross-activation of PKA [11] [12] [13] . The cGMP-dependent protein kinase (PKG) may also play a role, as endogenous membrane-bound PKG (probably PKG-II) and exogenous soluble PKG from lung (PKG-I), but not cGMP plus ATP alone, stimulated CFTR channel activity in excised patches [14] . In a similar study of fibroblasts overexpressing CFTR, Berger et al. [10] also failed to observe activation by cGMP plus ATP alone. However, in contrast to the findings of Lin et al. [14] , Berger et al. did not observe activation by exogenous PKG-I. The explanation for this discrepancy is not clear. In summary, the available evidence suggests at least two pathways for activation of CFTR by cGMP -cross-activation of PKA and phosphorylation by PKG.
Non-selective cation channels that exhibit direct, phosphorylation-independent activation have been identified in retinal and olfactory sensory receptor cells [15] . Cloning of the genes encoding these channel proteins [16, 17] revealed carboxy-terminal domains similar to a class of cyclic-nucleotide-binding domains (cNBDs) related to that of the catabolite gene activator protein (CAP) [18] . The mechanism of phosphorylationindependent channel activation has not been extensively investigated. In a recent study of chimeras constructed from retinal and olfactory channels, however, Goulding et al, [19] have suggested that such activation involves stabilization of the open state of the channel by the binding of a cyclic nucleotide.
In this study, we compare the response to cAMP and to cGMP of CFTR expressed in Xenopus oocytes. We show that inhibition of protein kinase activity does not diminish the response to cGMP, and that a domain in the proximal portion of the third cytoplasmic loop resembles CAP-related cNBDs. Moreover, we demonstrate that kinase-independent activation by cGMP is selectively altered by mutation of residues within this domain. We propose that there is a third cGMP activation pathway, in which direct binding to a CAP-related cNBD opens the CFTR channel.
Results
CFTR is activated by both cAMP and cGMP
Firstly, we examined the electrophysiological profile of CFTR expressed in Xenopus oocytes (microinjected with full-length human CFTR cRNA 1-8 days before assay), with native oocytes as controls. We compared four parameters: the time-course of current activation; the timedependence of current in response to voltage pulses; the current-voltage relationships; and the dose-dependence of current responses to cAMP or cGMP (Fig, 1) . In native oocytes, there was no current activation by either cyclic nucleotide (n > 3 oocytes per donor from > 10 donor frogs). In oocytes expressing CFTR, current activated by microinjected cAMP was similar to that reported previously using mixtures of forskolin plus the phosphodiesterase inhibitor IBMX (3-isobutyl-l-methylxanthine) plus a permeable cAMP derivative applied to the bath [20] [21] [22] . Current activated by microinjected cGMP resembled that activated by cAMP in all respects except dose-dependence (Fig. 1) . Current measured over a range of cyclic nucleotide concentrations displayed half-maximal activation (K2) at 0.3 + 0.1 tM cGMP and 4.4 ± 0.5 p.M cAMP, and approached saturation at 10 pIM cGMP and 30 ptM cAMP (Fig. Id) . These values were confirmed in oocytes from different donors. On this basis, 10 jM cGMP or 50 I.LM cAMP was employed as a saturating dose for the experiments described below.
The response to cGMP is dependent on the oocyte donor and is not additive to the response to cAMP The current response to cGMP was dependent on the order of addition of each cyclic nucleotide and on the donor from which the oocytes were obtained (Fig. 2) . Sequential addition was achieved by double microinjection using separate pipettes for cAMP and cGMP. When cAMP was applied first, CFTR current responses displayed no additivity in experiments on oocytes from three different donors (Fig. 2a, traces at left) . By contrast, when cGMP was applied first, the magnitude of the response was donor-dependent, and the subsequent application of cAMP elicited additional current (Fig. 2a , traces at right). As seen from the average values for the oocytes from each donor, cGMP elicited a submaximal response which was further stimulated by cAMP to a value slightly greater than ( Fig. 2b,d ; p < 0.01; n = 3 oocytes) or equal to ( Fig. 2c ; p > 0.2; n = 3) that seen with cAMP alone,
The absence of further current stimulation by cGMP when cAMP was applied first is consistent with activation of the same conductance by the two cyclic nucleotides. Moreover, the relatively large, but submaximal, responses elicited by cGMP in the oocytes from the donors shown in Figure 2c ,d were increased only to a level near that of cAMP alone, not to a level near the sum of both alone. This is also consistent with activation of the same conductance. For the oocytes from the donor shown in Figure  2b , however, the current was slightly, but significantly, greater (by 27 + 1 %; n = 3; p < 0.01) in response to cGMP plus cAMP, compared with cAMP alone or with cAMP plus cGMP. This result suggests there may be a small component of synergistic activation under these conditions. A somewhat smaller synergistic effect was also noted for the oocytes from the donor shown in Figure 2d .
The most striking difference between oocytes from different donors was in the current response to cGMP alone. When expressed as a percentage of current activated by cAMP alone, cGMP activated 18 + 2 % (Fig. 2b , n = 3), 70 ± 21 % (Fig. 2c , n = 3) or 95 3 % (Fig. 2d , n = 3) in these three donors. The current activated by cAMP was of similar magnitude in all donors, suggesting that nearly identical amounts of functional CFTR was expressed in the oocytes. Examination of nineteen donors in this way revealed two distinct populations that were distinguished by average cGMP responses of 20 3 % (n= 13 donors) and 87+3% (n=6 donors) relative to cAMP (Fig. 2e) . In donors from the former population that gave little or no response to 10 [pM cGMP, dose-response curves at elevated concentrations indicated K½ at 58 + 4 u.M cGMP (n = 3 complete dose-response curves; data not shown) and saturation near 300 .M cGMP. These values are consistent with cross-activation of PKA. The latter population with the large response to 10 M cGMP was used for the majority of subsequent experiments.
Pharmacology and anion selectivity are similar for CFTR currents activated by cAMP and cGMP
To examine further whether current activated by either cyclic nucleotide is attributable solely to CFTR channels, the pharmacology and anion selectivity of the two types of current were compared. First, we applied glibenclamide, a KATP channel inhibitor that is the most potent CFTR inhibitor yet identified [23] . The drug (600 M allied externally) inhibited 37 + 3 % (n = 3) or 51 + 15 % (n = 3) of current activated by cAMP (1569 + 43 nA, n = 8) or cGMP (1314 + 104 nA, n = 11), respectively (data not shown). Lower concentrations of glibenclamide (up to 100 iM) had no effect, indicating that it is less potent when applied to CFTR expressed in oocytes than in other cell systems. The addition of 1 mM DIDS or 1 mM IAA-94 had no inhibitory effect in these experiments, in agreement with previous reports (data not shown).
Next, we examined anion selectivity by lowering the chloride concentration in the bath from 90 mM to
I. dll,.UIIl ll. Lk lkI. tLd l,..llll. I1 I VIsal potential of current activated by cGMP shifted 23 + 1 mV (n = 4), comparable to the shift of 24 1 mV (n = 6) observed for current activated by cAMP (Fig. 3a,b) . Both values are close to the shift of 28 mV predicted from the Nernst equation for a perfectly selective pathway. Finally, iodide permeability and conductance measurements were determined as described by Anderson et al. [24] (Fig. 3c,d ). The replacement of chloride by iodide produced a similar shift in the current-voltage relationship for cAMP (PI/Pcl was 0.61 + 0.05 and GI/Gcl was 0.52 ± 0.07; n = 6) and C(UMI (,l/I-CI was U.J T U.u4 and i/Ci was 0.56 + 0.02; n = 3). Thus, both cyclic nucleotides activated anion-selective channels that were more permeable to chloride than iodide, a hallmark of CFTR current. Together, these results suggest that cAMP and cGMP act exclusively on CFTR channels, and they preclude secondary effects on other channels, such as the activation of an endogenous outward rectifier chloride channel (ORCC, Pi/Pc1 -1.5).
The response to cGMP is insensitive to protein kinase inhibition Current activated by the two cyclic nucleotides differed markedly in sensitivity to protein kinase inhibitors. Addition of the isoquinolinesulfonamide H-8 (100 ptM), a broad-spectrum kinase inhibitor, reduced cAMP-activated current by 57 + 10 %, but had no effect on cGMPactivated current (Fig. 4) . Addition of PKI 5 _24 (100 nM), a selective inhibitor of PKA, reduced cAMP-activated current by 76 ± 4 %, but also had no effect on cGMPactivated current. Addition of KT-5823 (1 IzM), a selective inhibitor of PKG [25] , had no effect on CFTR activation by either cyclic nucleotide. These results suggest that, whereas cAMP activates CFTR only by phosphorylation, cGMP may also activate it by a kinase-independent pathway. One possible explanation fr ci-rh -rr-xo1hn i ha, A-rfar rl-rl- Baseline current-voltage relationships were determined region of similarity was identified in the proximal porimmediately preceding the addition of cyclic nucleotides.
tion of the third cytoplasmic loop of CFTR (Fig. 5) . CFTR has 26 % identity to RET over the region shown, similar to the 16-22 % identity for the other sequences in the alignment (Fig. 5) . Of the seven RET residues modelled to interact directly with cGMP [26] , six are identical or highly conserved in CFTR. To evaluate the role of these residues in kinase-independent activation by cGMP, CFTR channels with single amino-acid substitutions at these sites were constructed (Table 1) . On the basis of the model for RET, the type of interaction between each residue and a specific cGMP chemical group could be predicted.
Single-residue substitutions can alter cGMP-dependent activation independently of cAMP-dependent activation
We examined the effect of these mutations by expressing wild-type and mutant channels in oocytes from the same donor; assays were performed on the same day. Three of the six channels with a single substitution showed a large reduction in cAMP-activated current relative to that of the wild-type channel (wild-type = 1650 + 54 nA; n = 4-9). The current was only 18 + 13 % (n = 3) of wild-type level for the mutant channel with the glutamate at position 407 substituted by glutamine (mutant E407Q, using the single-letter amino-acid code); 16 + 3 % (n = 4) for the L408A mutant; and 17 ±+ 1 % (n = 4) for the T421A mutant (data not shown). Furthermore, when three residues at positions 406-408 were simultaneously deleted (mutant GEL-), the current was only 4 2 % (n = 4) of the wild-type level (data not shown). A double substitution mutant (E407Q plus E403D) produced 63 + 8 % (n = 9) wildtype channel current (wild-type =2250 + 195 nA; n = 5; data not shown). Together, these results indicate that the substitution of one or two residues, or a small 
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suggesting that the mutants were processed normally and delivered to the plasma membrane (Fig. 7) . Experiments on the activation of wild-type CFTR and these three mutants by cGMP were performed in the simultaneous presence of PKI and KT-5823 to eliminate protein kinase activities. The G406A mutant responded normally to cGMP (Fig. 7a,c) . However, cGMP activation of the other two mutants differed from the wild-type response. The V397A mutant displayed a cGMP response that was enhanced by 66 + 19 % (n = 5; p < 0.05) relative to the wild-type channel (Fig. 7a,b) . The K420A substitution, which produced the largest effect, reduced the cGMP response by 75 ± 6 % (n = 4; p < 0.005; Fig. 7a,c) compared with the wild-type channel. This result was confirmed in an identical experiment in which the cGMP response was reduced 84 ± 5 % (n = 5; p < 0.001) compared with the wild-type channel (1250 + 124 nA).
Discussion
Donor-dependence of direct activation
The observed distribution in the magnitude of direct activation by cGMP between oocytes from different donors, together with the failure of other studies to report such a direct effect, suggests that this pathway may be inoperative under many experimental conditions. At least three factors could contribute to the donordependence of direct activation. First, differences in the activity of cyclic nucleotide phosphodiesterase (PDE) may exist among donors. Oocytes express more than one PDE [27] , but their individual PDE types have not been characterized extensively [28] . Hydrolysis of cGMP may occur in crude homogenates but not in intact oocytes [29] , and hydrolysis of cAMP is stimulated by insulin and insulin-like growth factor 1 [30] , indicating that oocyte PDEs are under hormonal regulation. In guinea-pig ventricular myocytes, cGMP enhances submaximallystimulated catecholamine-induced chloride current through milrinone-sensitive cGMP-inhibited PDE (type III) [31] . In the present study, however, a role for PDE type III can be precluded as the PKA inhibitors H-8 and PKI did not diminish activation by cGMP. deletion, can have a range of negative effects on cAMPactivated current. For this group of mutations, we were unable to distinguish between an effect on gating by cAMP and the introduction of a defect in the processing of the protein.
The three other single-substitution mutants (V397A, G406A and K420A) produced functional channels that responded to cAMP in a manner identical to wild type, Direct activation may also be modulated by phosphorylation. For example, the affinity of RET for cyclic nucleotides appears to be modulated by phosphatase activity [32] , and dual control of channel activity by phosphorylation and direct effects have been described for the nonselective cation channel from renal inner medulla [33, 34] . However, the only consensus PKA site within the CFTR cNBD -serine at position 422 -is an unlikely candidate for phosphorylation as it is a poor substrate for PKA in vitro [9] . This does not preclude the possibility of phosphorylation at cryptic sites by PKA or other kinases. Cryptic phosphorylation activates CFTR [5] , and it will be important to determine the relationship between cryptic phosphorylation and direct activation.
Finally, for the olfactory sensory channel (OLF), the presence of bound calmodulin (CaM) shifts the cGMP activation curve to the right by one full order of magnitude [35] . Thus, it will be interesting to determine whether CaM influences CFTR activation by the direct pathway. Other possibilities, not considered here, may account in whole, or in part, for the donor-dependence of direct activation.
Relation to other cyclic-nucleotide-binding domains
Cyclic-nucleotide-binding domains appear in a variety of proteins having diverse functions [18] . The cNBDs identified are highly degenerate at the primary sequence level. As only one crystal structure of such a domain has been available, gaps exist in our knowledge of the contacts that individual residues make with the cyclic nucleotides. The CFTR residues between TM6 and NBF1 span a region large enough to form the eight-stranded antiparallel roll observed in the crystal structure of CAP [36, 37] . The two most conserved 3 strands (defined here as having one-third or more of all strand residues encoded by three or fewer possibilities) in an alignment of 24 sequences are (2 and (37 [18] . These two strands may correspond to residues 373-378 and 418-423 in CFTR. The invariant glycine residues found at the ends of the 33 strand in CAP are not conserved in CFTR. The amino and carboxyl termini, which are the most degenerate portions of domains identified previously, may be contributed to by part of TM6 and NBF1, respectively, perhaps providing links to the conduction pathway and other regulatory domains. (We note with interest that a second CAP-related structure has been solved recently [38] ).
Our mutagenesis experiments address the likelihood of three potential sites for cGMP contact. The substitution of the valine at position 397 for an alanine resulted in a mildly enhanced cGMP response -opposite to the predicted result. As the smaller hydrophobic surface provided by alanine was stimulatory, valine is unlikely to make an important hydrophobic interaction with the guanine ring of cGMP. Uncertainty surrounding purine contact sites is well noted [18] . For example, the crystal structure of CAP indicates cAMP binding in the anti conformation, whereas solution nuclear magnetic resonance studies with CAP and kinases suggest binding in the syn conformation. Although our experiment indicates that valine 397 is in an important location, it may require detailed structural information to determine its precise role in activation by cGMP.
The substitution of an alanine for the glycine at position 406, which replaced the minimal proton with a bulkier methyl group, had no effect on activation by cGMP As this glycine is invariant, the substitution was predicted to be disruptive. However, a hydrogen-bond between the ribose 2'-hydroxyl group and the amino group of this residue's peptide bond could, in principle, occur with any substitution tolerated by the rest of the domain. It would be of interest to compare the effects of substitutions at this position in analogous domains from other proteins.
The substitution of an alanine for the lysine at position 420 was predicted to disrupt an ionic interaction with exocyclic phosphate oxygen, resulting in reduced activation by cGMP. We observed a profoundly diminished response, which suggests that a charge interaction at this position plays an important role in direct activation by cGMP. CFTR appears unique in that lysine contributes the positive charge, instead of the arginine residue encountered in all other domains. Further experiments will be required to determine the cyclic-nucleotide specificity and binding activity of this domain.
The available evidence suggests that CFTR functions as a monomer [39] , whereas CAP and kinases are known to function as dimers. A truncated CFTR molecule engineered to terminate at residue 836 (of the native 1480 residues) produced a homomultimer (probably a homodimer) [40] , suggesting that the internal symmetry of intact CFTR may replace dimer formation. However, the analogous region in the second half of CFTR (residues 1151-1218) does not resemble a CAP-related cNBD, suggesting that each full-length CFTR monomer would bind only one molecule of cGMP. By comparison, the subunit stoichiometry of sensory channels has not been determined, but is presumed to be tetrameric, similar to that of voltage-dependent potassium channels.
Another class of channels, permeable to potassium and calcium ions, display voltage-dependent gating which may be modified directly by cAMP. The ether-a-go-go gene product, Eag, and other related channels from Drosophila to mammals have a putative cNBD in the carboxy-terminal portion of the protein [41, 42] . These cNBDs do not have a threonine residue corresponding to that present in RET, PKGs and CFTR (see alignment in [43] and Fig. 5) , consistent with the absence of cGMP effects on the Eag current [41] .
Physiological role and significance of direct activation in CFTR channel gating
The presence of a cNBD in CFTR is unexpected because of the dominant role that cross-activation appears to play in secretion stimulated by cGMP. The domain may provide a pathway for activation at a level of cGMP below that needed for cross-activation. Previously, a twofold increase in measurable cGMP was observed to have no effect on trans-epithelial secretion [441. That result is not directly comparable to the present study, however, as the concentration of cGMP in the cells expressing CFTR was not determined. Alternatively, the domain may function only under certain basal conditions. Studies mentioned previously indicate that phosphorylationdependent activation is complex. Further investigation will be required to determine whether the cNBD activates alone, or in conjunction with other gating mechanisms of this highly regulated channel.
In airway epithelial cells, evidence exists for the expression of nitric oxide synthase [45, 46] , soluble guanylate cyclase and C-type natriuretic peptide receptor [47] , suggesting at least two pathways for the generation of cGMP in this tissue. However, a cGMP effector target has not been clearly identified. Most expression of CFTR occurs in submucosal glands, notably serous epithelial cells of secretory tubules and not surface epithelium [48] . It is of critical importance to define further the distribution of messengers and effectors among the myriad cell types in the lung, in order to resolve the role of cGMP in the activation of airway CFTR.
None of the thirty most-common mutations associated with the cystic fibrosis disease occurs within this 82-residue region [49] . As many mutant CFTRs display some channel activity (reviewed in [3] ), pharmacological activation of this domain may be beneficial. Understanding the range of cGMP effects that have been reported therefore represents a major hurdle before such an approach would become feasible. Nevertheless, if mutant protein trapped within intracellular compartments can be retargeted to the plasma membrane (for example, see the study by Stanton and coworkers [50] ), then drugs designed for direct activation would provide an alternative to less-specific compounds that act by the global stimulation of signaling pathways.
Conclusions
The study described here demonstrates a new pathway for the activation of CFTR. Experiments with protein kinase inhibitors indicate that cGMP can activate the channel by a kinase-independent mechanism. Analysis of the amino-acid sequence of CFTR reveals that the amino-terminal region of the third cytoplasmic loop resembles known cyclic-nucleotide-binding domains. Two point mutations in this domain, predicted to disrupt direct contact with cGMP, alter the response to cGMP with no effect on the response to cAMP. Together, the results support the identification of a site for direct cyclic-nucleotide activation of CFTR. This domain may provide a useful target for pharmacological intervention in cystic fibrosis.
Materials and methods
Oocytes
Frogs (X. laevis) were obtained from Xenopus I (Ann Arbor, Michigan). Oocytes were prepared and maintained at 18 C in modified Barth's saline (MBS) supplemented with antibiotics as described previously [51] . Oocytes of 1 1.2 mm diameter were used. Reported concentrations are based on a free intracellular volume of 500 nl, to account for abundant yolk granules in the vegetal hemisphere.
Expression of CFTR
Full-length human CFTR cDNA [52] , flanked by the 5' untranslated region from the Xenopus 3-globin gene and a 3' poly A 23 C 3 ( 1 tail, was transcribed from pBluescript (Stratagene) using T7 RNA polymerase according to manufacturer's recommendations (Promega). The cRNA (5 ng per oocyte) was injected into oocytes 1-8 days prior to assay for CFTR current.
Electrophysiology Technical details were as described previously [51] . All recordings were performed in MBS, which contained 90. 4 Values reported in the text or displayed in bar graphs are means + standard error for the change in response to cyclic nucleotides measured at a holding potential of-100 mV (-AI). The number (n) of observations reported refers to oocytes unless frogs (donors) are mentioned. Statistical comparisons were performed using Student's t-test. All comparisons between control and experimental groups were made on oocytes from the same donor assayed on the same day. Only natural cyclic nucleotides were used, in order to approximate closely physiological conditions, and to avoid the possibility that derivatives may behave differently for direct activation. For sequential addition experiments, each cyclic nucleotide was injected in a 25 nl volume to maintain the total added volume at 50 nl. Saturating doses (50 FtM cAMP and 10 IpM cGMP) were employed in all experiments, except that 5 aM cGMP was used for kinase inhibitor studies. Permeability and conductance ratios were calculated as described [24] .
Mutagenesis
The 1 kb CFTR XbaI-SphI restriction fragment was excised from the transcription vector, cloned into pALTER (Promega), mutagenized using oligonucleotides with silent restriction sites to facilitate screening, and transferred back to the original vector for sequencing in both directions. Mutant CFTR was expressed in oocytes as above.
Reagents PKI was obtained from Peninsula, KT5823 from Kamiya, H-8 from Research Biochemicals International, and cyclic nucleotides from Sigma or Calbiochem. All other reagents were from Sigma, Boehringer Mannheim, Promega or New England Biolabs.
